Compare JFR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFR | CAPR |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2011 |
| Metric | JFR | CAPR |
|---|---|---|
| Price | $7.18 | $28.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $35.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $4.30 |
| 52 Week High | $8.59 | $40.37 |
| Indicator | JFR | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 26.27 | 49.29 |
| Support Level | N/A | $25.33 |
| Resistance Level | $7.97 | $30.06 |
| Average True Range (ATR) | 0.07 | 2.13 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 0.00 | 7.67 |
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.